Barclays PLC Has $884,000 Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Barclays PLC grew its position in Tyra Biosciences, Inc. (NASDAQ:TYRA) by 200.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 37,625 shares of the company’s stock after acquiring an additional 25,106 shares during the period. Barclays PLC owned about 0.07% of Tyra Biosciences worth $884,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. FMR LLC raised its stake in Tyra Biosciences by 0.8% in the third quarter. FMR LLC now owns 3,372,850 shares of the company’s stock valued at $79,296,000 after buying an additional 26,187 shares during the period. Janus Henderson Group PLC bought a new stake in Tyra Biosciences in the 3rd quarter valued at $24,994,000. Perceptive Advisors LLC raised its stake in Tyra Biosciences by 50.5% in the 2nd quarter. Perceptive Advisors LLC now owns 1,007,367 shares of the company’s stock valued at $16,108,000 after acquiring an additional 338,208 shares during the period. State Street Corp lifted its holdings in Tyra Biosciences by 4.4% during the 3rd quarter. State Street Corp now owns 384,732 shares of the company’s stock valued at $9,045,000 after purchasing an additional 16,248 shares during the last quarter. Finally, Ally Bridge Group NY LLC increased its holdings in shares of Tyra Biosciences by 2.0% in the third quarter. Ally Bridge Group NY LLC now owns 270,075 shares of the company’s stock valued at $6,349,000 after purchasing an additional 5,415 shares during the last quarter. 84.14% of the stock is currently owned by institutional investors and hedge funds.

Tyra Biosciences Stock Performance

NASDAQ:TYRA opened at $15.94 on Wednesday. The company has a market cap of $806.61 million, a price-to-earnings ratio of -9.90 and a beta of 1.04. Tyra Biosciences, Inc. has a fifty-two week low of $12.17 and a fifty-two week high of $29.60. The stock has a fifty day moving average price of $15.40 and a 200-day moving average price of $19.22.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.01). Research analysts predict that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on TYRA shares. Wedbush restated an “outperform” rating and set a $28.00 target price on shares of Tyra Biosciences in a research note on Friday, October 25th. Bank of America upgraded Tyra Biosciences from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $22.00 to $31.00 in a report on Friday, October 18th. UBS Group started coverage on Tyra Biosciences in a research note on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a research report on Monday. Finally, Oppenheimer boosted their target price on shares of Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research report on Thursday, September 19th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tyra Biosciences presently has an average rating of “Buy” and an average price target of $30.50.

Insider Buying and Selling

In other Tyra Biosciences news, CEO Todd Harris sold 19,084 shares of the company’s stock in a transaction on Monday, October 21st. The stock was sold at an average price of $27.90, for a total transaction of $532,443.60. Following the completion of the sale, the chief executive officer now directly owns 1,355,927 shares in the company, valued at $37,830,363.30. This represents a 1.39 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Alan Fuhrman purchased 9,500 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was acquired at an average price of $16.00 per share, for a total transaction of $152,000.00. Following the purchase, the chief financial officer now owns 12,849 shares in the company, valued at approximately $205,584. The trade was a 283.67 % increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 74,125 shares of company stock worth $1,583,097. Corporate insiders own 15.40% of the company’s stock.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.